Roethlisberger Dieter, Mahler Hanns-Christian, Altenburger Ulrike, Pappenberger Astrid
F. Hoffmann-La Roche Ltd., Pharmaceutical Development and Supplies, Pharma Technical Development Biologics EU, Basel, Switzerland.
F. Hoffmann-La Roche Ltd., Pharmaceutical Development and Supplies, Pharma Technical Development Biologics EU, Basel, Switzerland.
J Pharm Sci. 2017 Feb;106(2):446-456. doi: 10.1016/j.xphs.2016.09.034. Epub 2016 Nov 23.
Parenteral products should aim toward being isotonic and euhydric (physiological pH). Yet, due to other considerations, this goal is often not reasonable or doable. There are no clear allowable ranges related to pH and osmolality, and thus, the objective of this review was to provide a better understanding of acceptable formulation pH, buffer strength, and osmolality taking into account the administration route (i.e., intramuscular, intravenous, subcutaneous) and administration technique (i.e., bolus, push, infusion). This evaluation was based on 3 different approaches: conventional, experimental, and parametric. The conventional way of defining formulation limits was based on standard pH and osmolality ranges. Experimental determination of titratable acidity or in vitro hemolysis testing provided additional drug product information. Finally, the parametric approach was based on the calculation of theoretical values such as (1) the maximal volume of injection which cannot shift the blood's pH or its molarity out of the physiological range and (b) a dilution ratio at the injection site and by verifying that threshold values are not exceeded. The combination of all 3 approaches can support the definition of acceptable pH, buffer strength, and osmolality of formulations and thus may reduce the risk of failure during preclinical and clinical development.
注射用产品应尽量做到等渗和等水(生理pH值)。然而,出于其他考虑,这一目标往往不合理或无法实现。目前尚无关于pH值和渗透压的明确允许范围,因此,本综述的目的是在考虑给药途径(即肌肉注射、静脉注射、皮下注射)和给药技术(即推注、推注、输注)的情况下,更好地理解可接受的制剂pH值、缓冲强度和渗透压。该评估基于三种不同的方法:传统方法、实验方法和参数方法。定义制剂限度的传统方法基于标准pH值和渗透压范围。可滴定酸度的实验测定或体外溶血试验提供了更多的药品信息。最后,参数方法基于理论值的计算,如(1)不会使血液pH值或摩尔浓度超出生理范围的最大注射体积,以及(b)注射部位的稀释率,并通过验证不超过阈值。这三种方法的结合可以支持确定制剂可接受的pH值、缓冲强度和渗透压,从而可能降低临床前和临床开发过程中的失败风险。